S&P affirms CCS

Standard & Poor's said it affirmed its B-corporate credit rating on CCS Medical

Inc.

In addition, the ratings were removed from CreditWatch, where they were placed with positive implications on May 16, the agency said.

The outlook is positive.

S&P noted that the ratings continue to reflect CCS's exposure to reimbursement decisions by third-party payors, uncertainties related to the impact of Medicare competitive bidding for CCS's diabetes supplies and the company's still-aggressive leverage.

These risks are somewhat mitigated by the growing market for CCS's services, its relatively diversified revenue and payor mixes, and the potential for a revival of the company's IPO plans, according to the agency.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.